Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers.
The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies.
The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development.
Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants.
The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630.
Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 20, 24 | -0.70 Increased by +2.78% | -0.75 Increased by +6.67% |
| Feb 26, 24 | -1.14 Decreased by -80.95% | -0.88 Decreased by -29.55% |
| Nov 6, 23 | -0.99 Decreased by -13.79% | -1.01 Increased by +1.98% |
| Aug 8, 23 | -0.92 Decreased by -12.20% | -0.82 Decreased by -12.20% |
| May 8, 23 | -0.72 Increased by +7.69% | -0.81 Increased by +11.11% |
| Feb 27, 23 | -0.63 Increased by +11.27% | -0.82 Increased by +23.17% |
| Nov 7, 22 | -0.87 Decreased by -20.83% | -0.84 Decreased by -3.57% |
| Aug 9, 22 | -0.82 Decreased by -36.67% | -0.85 Increased by +3.53% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by -100.00% | -108.43 M Decreased by -47.87% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 3.82 M Decreased by -58.05% | -98.30 M Decreased by -62.87% | Decreased by -2.57 K% Decreased by -288.26% |
| Mar 31, 23 | 7.01 M Decreased by -7.44% | -58.51 M Decreased by -2.02% | Decreased by -834.13% Decreased by -10.23% |
| Dec 31, 22 | 15.33 M Increased by +62.05% | -56.51 M Decreased by -7.27% | Decreased by -368.60% Increased by +33.80% |
| Sep 30, 22 | 3.36 M Increased by +204.81% | -73.33 M Decreased by -38.51% | Decreased by -2.19 K% Increased by +54.56% |
| Jun 30, 22 | 9.12 M Increased by +4.81% | -60.35 M Decreased by -36.24% | Decreased by -662.08% Decreased by -30.00% |
| Mar 31, 22 | 7.58 M Decreased by -25.20% | -57.34 M Decreased by -54.25% | Decreased by -756.73% Decreased by -106.22% |
| Dec 31, 21 | 9.46 M Increased by +8.10% | -52.68 M Decreased by -54.01% | Decreased by -556.83% Decreased by -42.46% |